Ectica Welcomes You With Free VIP Registration to Proventa’s Oncology Strategy Meeting USA 2022
Ectica Technologies is delighted to sponsor the 5th Annual Oncology Strategy Meeting organized by Proventa International taking place on May
Read moreEctica Technologies is delighted to sponsor the 5th Annual Oncology Strategy Meeting organized by Proventa International taking place on May
Read moreTremelimumab, in conjunction with Imfinzi, has been accepted under priority review for patients with unresectable liver cancer in the United
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb has announced that OpdualagTM , a new, first-in-class, fixed-dose combination of nivolumab and relatlimab, administered as one intravenous infusion,
Read moreBased on data obtained from Phase II and the Phase I studies, Abecma has received approval in Japan for the
Read moreThe novel 3DProSeed ® StromaLine ® developed by Ectica is an advantageous collection of pre-developed and well characterized stromal models
Read moreFrench pharma giant Sanofi and British pharmatech business Exscientia revealed a ground-breaking research cooperation and licensing agreement to develop up
Read moreRhizen Pharmaceuticals has started dosing in a phase I/Ib trial to assess the efficiency of PARP inhibitor (RP12146) in advanced
Read moreAgilent’s PD-L1 IHC 22C3 pharmDx can now be used as an aid in identifying Triple-Negative Breast Cancer (TNBC) patients for
Read moreThe first two projects funded within the translational BRIDGE beLAB1407 collaboration will focus on new mechanisms to treat cancer, Evotec
Read moreKEYTRUDA® has been granted approval as a first-choice treatment in combination with chemotherapy for patients with locally recurrent unresectable or
Read more